Key result
Sunitinib and sorafenib treatment for metastatic renal cell carcinoma was associated with cardiac events in 33.8% of eligible patients, with 9.4% requiring intermediate or intensive care.
Why the study?
Does sunitinib or sorafenib cause cardiac events in patients with metastatic renal cell carcinoma?
Population
74 eligible patients (out of 86 treated) with metastatic renal cell carcinoma intended for TKI treatment
Design
Cohort
Authors
Loading...
Supports cardiac monitoring during sunitinib or sorafenib; leaves open causality and optimal strategies.
Observational (n=86)
No
Does sunitinib or sorafenib cause cardiac events in patients with metastatic renal cell carcinoma?
Treatment with sunitinib or sorafenib in metastatic renal cell carcinoma is associated with a high but manageable incidence of cardiac toxicity, emphasizing the need for routine cardiovascular monitoring.
Schmidinger et al. (2008) conducted an observational in Metastatic renal cell carcinoma (n=86). Sunitinib or sorafenib was evaluated on Cardiac event (increased enzymes, symptomatic arrhythmia requiring treatment, new left ventricular dysfunction, or acute coronary syndrome). Sunitinib and sorafenib treatment for metastatic renal cell carcinoma was associated with cardiac events in 33.8% of eligible patients, with 9.4% requiring intermediate or intensive care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: